Important Rating: Will Aegis Capital New Ratings Coverage Help Mediwound Ltd (NASDAQ:MDWD) Stock Today?

November 28, 2016 - By Michael Collier

Important Rating: Will Aegis Capital New Ratings Coverage Help Mediwound Ltd (NASDAQ:MDWD) Stock Today?

Why Aegis Capital Gives Mediwound Ltd (NASDAQ:MDWD) $11.00 Price Target

Equity analysts at Aegis Capital has started coverage on shares of Mediwound Ltd (NASDAQ:MDWD) in a an analyst note sent to investors on Monday, 28 November. The company set a Buy rating on the stock. Aegis Capital’s target of $11.00 suggests potential of 103.33% from the stock’s close price.

Mediwound Ltd (NASDAQ:MDWD) Ratings Coverage

Out of 4 analysts covering MediWound (NASDAQ:MDWD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15 is the highest target while $13 is the lowest. The $14 average target is 161.68% above today’s ($5.35) stock price. MediWound has been the topic of 4 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by SunTrust on Wednesday, March 23. The firm earned “Outperform” rating on Monday, August 10 by Credit Suisse. As per Wednesday, August 17, the company rating was initiated by Wells Fargo.

About 23,650 shares traded hands or 18.77% up from the average. Mediwound Ltd (NASDAQ:MDWD) has declined 37.80% since April 25, 2016 and is downtrending. It has underperformed by 43.81% the S&P500.

Analysts await Mediwound Ltd (NASDAQ:MDWD) to report earnings on January, 23. They expect $-0.25 EPS, up 30.56% or $0.11 from last year’s $-0.36 per share. After $-0.26 actual EPS reported by Mediwound Ltd for the previous quarter, Wall Street now forecasts -3.85% EPS growth.

MediWound Ltd. is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The company has a market cap of $122.86 million. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. It currently has negative earnings. NexoBrid is based on the Company’s proteolytic enzyme technology.

According to Zacks Investment Research, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.”

MDWD Company Profile

MediWound Ltd., Incorporated on January 27, 2000, is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company’s proteolytic enzyme technology. It offers NexoBrid in Europe and Israel.

Another recent and important Mediwound Ltd (NASDAQ:MDWD) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on March 21, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>